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Abstract 
Progressive xercise intolerance was associated with a decreased maximal rate of ubiquinol cytochrome c reductase (complex III) 
activity in the muscle mitochondria of the studied patient and with a thirty five-fold increase in the 150 for antimycin A. In contrast, 
myxothiazol sensitivity was not altered. Complex III activity was stable at 37°C, but progressively decreased at4°C. An heteroplasmic G 
to A mutation at position 15615 of the mitochondrial DNA, resulting in the replacement of the highly conserved Gly29 o in cytochrome b 
by Asp, was identified. Histochemical studies showed increased cytochrome oxidase and succinate dehydrogenase activities under the 
sarcolemma of type I fibres, After partial extraction of mitochondria from the muscle, the residual pellet contained a lower percentage of
the mutation than did whole muscle, suggesting that the percentage ofmutation is higher in the most readily extracted mitochondria, most 
probably present under the sarcolemma. In the current 8 transmembrane helix model of cytochrome b, Gly29 o lies at the end of the sixth 
transmembrane h lix, facing the intermembrane space and close to the presumed sites of interaction between cytochrome b, the 
iron-sulfur protein and the 9.5 kDa protein. Since immunoblotting experiments howed a relative decrease in the proportions of these 
three subunits in the patient's mitochondria compared with the other complex III subunits, it is probable that the complex III instability 
and the relative decrease in these subunits are related to the mutation. The relationship between the decrease in the apparent affinity for 
antimycin A and the instability of complex III are discussed. 
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1. Introduction 
Complex III (bcl complex or ubiquinol cytochrome c
reductase, EC 1.10.2.2) catalyzes proton translocation 
across the mitochondrial inner membrane during electron 
transfer between ubiquinol and cytochrome c. The enzyme 
purified from bovine heart mitochondria contains eleven 
distinct peptide subunits [1]: the largest subunits, core 
proteins I and II are important for the correct assembly of 
complex III; the next largest peptides, cytochromes b and 
cl and the 'Rieske' iron-sulfur protein, are the central 
catalytic units [1,2]. Among the six smallest subunits are 
the 13.4 kDa protein, the 9.5 kDa quinone-binding protein, 
the 9.2 kDa 'hinge' protein, essential for cytochrome c
binding, the 8.0 kDa protein that has been shown to be the 
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mitochondrial targetting sequence of the iron-sulfur pro- 
tein, and the 7.2 and 6.4 kDa proteins. Cytochrome b, the 
only subunit encoded by mtDNA [3], contains two heme 
groups and is the major transmembrane component of 
Complex III [4]. MtDNA sequences evolve 6-17 times 
faster than nuclear DNA sequences and 43 polymorphisms 
of the cytochrome b gene sequence have been described in 
human [5]. The majority either have no effect on the 
protein sequence or are commonly found in the normal 
population and have no known influence on cytochrome b 
function or assembly and on complex III activity. A de- 
cline in cytochrome b content during aging has been 
associated, at least in females, with a decrease in ubiquinol 
cytochrome c reductase activity [6]. However, the cause of 
the reduction in cytochrome b expression is still discussed. 
No specific mutation of human cytochrome b has been 
convincingly correlated to modifications of human cy- 
tochrome b properties, until now. Two mutations associ- 
ated to Leber Hereditary Optic Neuropathy (LHON) have 
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been described in position 15257 or 15812 of the mtDNA 
sequence, both replacing a G with an A and converting 
Aspm to Asn and Val356 to Met, respectively [7]. Since 
ASP171 is highly conserved phylogenically and since all 
vertebrates have either a Val, Leu or Ile at position 356, 
these substitutions might have functional significance. 
However, no alteration in complex III activity has yet been 
demonstrated in the mitochondria of the blind patients 
bearing these mutations. Recently, a new G to A transition 
in position 15615 of the mtDNA sequence [8] was discov- 
ered in a patient presenting with progressive xercise 
intolerance linked to a decrease ubiquinol cytochrome c 
reductase activity in the muscle mitochondria [9]. This 
mutation replaces Gly290 of cytochrome b by Asp and, 
since GlY290 is conserved in cytochrome b from more than 
900 species [10], this change is therefore a good candidate 
for explaining the Complex III deficiency. 
This paper describes the first example in human of a 
mitochondrial complex III with modified properties related 
to a cytochrome b mutation. 
mannitol, 0.5% bovine serum albumin, 1 mM EGTA, 10 
mM Hepes, adjusted to pH 7.4 with KOH). It was then 
incubated for 5 min with 1 mg of subtilisin per g of muscle 
in 5 ml of buffer A, then diluted with 25 ml of buffer A 
and the mixture centrifuged at 15 000 X g for 5 min. The 
pellet was suspended in 30 ml of buffer A with a motor- 
driven Teflon-glass Potter homogenizer. The homogenate 
was centrifuged at 1000 X g for 5 min before filtering the 
supernatant through four layers of cheese-cloth o remove 
fat and fibrous tissue. The pellet was resuspended in 20 ml 
of buffer A, homogenized again, centrifuged and the su- 
pernatant filtered as above. The final pellet (C 1) was kept 
at - 80°C for DNA extraction, while the two filtrates were 
centrifuged at 15000 X g for 10 min. The mitochondria 
enriched pellets were suspended in 1.5 ml of buffer A, 
centrifuged at 1000 X g for 5 min and the supernatant was 
centrifuged at 15000 X g for 10 min. The final mitochon- 
drial fraction was suspended in a minimal volume of 
buffer A (approx. 20-50 mg protein/ml). 
2.4. Oxypolarographic measurements 
2. Materials and methods 
2.1. Chemicals 
Chemicals were supplied either by Sigma Chemical Co. 
(St. Louis, MO, USA) or by Boehringer (Mannheim, Ger- 
many) except otherwise indicated. Taq DNA polymerase 
was from Appligene. 
2.2. Collection of specimens 
All experiments were performed with the informed 
consent of the patients. Controls were from patients com- 
plaining of muscle problems but that were subsequently 
shown to have no morphological, histochemical, biochemi- 
cal or genetic basis. The clinical condition of the patient 
with progressive xercise intolerance has been previously 
described [9]. 
A biopsy was taken from the vastus lateralis by open 
surgery, under local anesthesia. A sample was promptly 
snap-frozen i isopentane cooled by liquid nitrogen before 
making 8-/zm thick transverse sections. Two samples were 
kept in liquid nitrogen for molecular biology and enzy- 
matic analysis. Another sample was transported to the 
laboratory within half an hour in ice-cold transport buffer 
(150 mM KCI, 1 mM EDTA and 10 mM potassium 
phosphate buffer, pH 7.4), for mitochondria solation. 
2.3. Preparation of mitochondria 
All the following operations were conducted at 0-4°C. 
The muscle sample was stripped of fat and connective 
tissues, weighed, finely chopped with scissors and washed 
in homogenization buffer A (70 mM sucrose, 220 mM 
Substrate oxidation was measured by oxypolarography 
in an Hansatech oxygraph equipped with a Clark electrode 
using about 100 /zg of mitochondrial proteins in 0.5 ml of 
respiratory medium (225 mM sucrose, 1 mM EDTA, 5 
mM MgC12, 10 mM potassium phosphate, 10 mM Tris- 
HC1, pH 7.4), in the presence of the indicated substrates. 
After 2 min of incubation at 30°C, 80/xM ADP was added 
and the rate of oxygen consumption was measured. Protein 
concentration was determined with the bicinchoninic acid 
reagent according to the manufacturer's instructions 
(Pierce). Those mitochondria not used for polarographic 
measurements were treated by the addition of a cocktail of 
protease inhibitors (4 mM phenylmethylsulfonyl fluoride, 
1 mM EDTA and 2 mM e-aminocaproate, final concentra- 
tions), centrifuged at 17 000 X g for 20 min and the pellets 
stored at -80°C for enzymatic or immunological studies. 
2.5. Measurement of ubiquinol cytochrome c reductase 
activity 
Ubiquinol cytochrome c reductase activity was mea- 
sured either in freeze-thawed mitochondria suspended at 
about 0.2 mg of protein per ml of 10 mM potassium 
phosphate buffer, pH 7.5, containing the protease inhibitor 
cocktail, or in muscle homogenate prepared by homoge- 
nization (Teflon-glass Potter homogenizer) of 20-50 mg 
of frozen muscle in 0.4-1 ml of 10 mM potassium phos- 
phate buffer, pH 7.5, containing the protease inhibitor 
cocktail, followed by centrifugation at 600 X g for 5 min 
to remove nuclei and muscle fragments. Unless otherwise 
indicated, ubiquinol cytochrome c reductase activity was 
measured at 37°C from the quasi-linear initial rate of 
cytochrome c reduction at 550 nm in 1 ml of buffer 
containing 55 mM potassium phosphate, pH 7.5, 2.5 mg of 
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fatty-acid free bovine serum albumin, 1 mM KCN, 0.1 
mM horse cytochrome c, 20/xg of rotenone and 60/zM of 
decylubiquinol prepared by dithionite reduction of 20 mM 
decylubiquinone, dissolved in DMSO (by heating for 10 
min at 37°C), followed by elimination of excess dithionite 
by centrifugation at 17 000 × g for 15 min. After 1 min, 
2.5 to 25 /xg of proteins (mitochondria or muscle ho- 
mogenate) were added and the quasi-linear initial rate of 
cytochrome c reduction measured. To test the inhibition of 
complex III by antimycin or myxothiazol, the mitochon- 
dria were preincubated for 1 min with the inhibitor before 
addition to the reaction cuvette. The data were calculated 
after subtraction of the rate observed either in the absence 
of protein or in the presence of 2 nmol of antimycin or 
myxothiazol. Myxothiazol and antimycin A were dissolved 
in absolute thanol. 
2.6. Immunological studies 
Previously described procedures [9] were performed, 
using polyclonal rabbit anti-complex III antibodies, mono- 
clonal mouse anti-F1-ATPase /3 subunit antibody [11] or 
antibodies against subunits of complex IV (a monoclonal 
anti-subunit IV and a polyclonal anti-subunit II, generous 
gifts from B. Kadenbach and A. Lombes, respectively). 
Complex III proteins reacting with the antibodies were 
identified by comparing the migration pattern obtained 
using human mitochondria with that of complex III iso- 
lated from beef heart in the gel system described by 
Sch~igger et al. [12]. Control and patient mitochondrial 
proteins (30 /zg), separated by tricine-SDS-PAGE by the 
method of Sch~igger and von Jagow [13] on a 10% poly- 
acrylamide separating el, were transferred to Immobilon 
P [14]. The proportion of each Complex III subunit present 
in the patient's mitochondria was estimated and compared 
with that from control mitochondria present on the same 
blot, using primary antibodies directed against he tested 
protein and peroxidase-labelled second anti-mouse or anti- 
rabbit immunoglobulin antibodies (Biosis) and the ECL 
immunodetection technique (Amersham). Preliminary ex- 
periments were performed with various amounts of mito- 
chondria in order to determine the optimal antibody dilu- 
tions and exposure times to avoid over-exposure of the 
X-ray film and to obtain signals representative of the 
protein amounts present on the nitrocellulose blot. The 
films were analysed by densitometry using a Sony camera 
coupled to a Macintosh IIFX and the image analysis 
software of Biolab. 
2.7. Mt DNA analysis 
showed a G15615A mutation in the mtDNA, resulting in the 
generation of an Aat II restriction site in cytochrome b
gene, and a T14766C mutation resulting in the loss of a 
MseI restriction site. Cytochrome b fragments were ampli- 
fied by polymerase chain reaction, using the 20-mer primers 
H15437 and L15777, for the first mutation, and H14640 
and L14815, for the other, at concentrations of 0.5 /zM. 
The numbers used are those of the Cambridge mtDNA 
sequence [15] and the letter represents he heavy or light 
chain, respectively. The amplification was conducted in 
the presence of 0.2 mM of each dNTP, of 1 U of Taq 
DNA polymerase (Appligene) and of the Appligene buffer. 
Thirty cycles each of 1 min denaturation at 93°C, 1 min 
annealing (53°C, in the first case, or 55°C, in the second) 
and 1 min extension at 72°C were carried out. The ampli- 
fied DNA was digested with either Aat II at 37°C (muta- 
tion 15615) or Mse I (Tru 91) at 65°C (mutation 14766), as 
recommended by the enzyme manufacturer (Boehringer). 
After separation of the fragments by agarose lectrophore- 
sis in TBE buffer (Tris-HCl 50 mM; boric acid 50 mM; 
EDTA 1 mM; pH 8.0) and staining with ethidium bromide, 
the relative amount of DNA, before and after restriction 
enzyme digestion was estimated by densitometric s anning 
of the gel, using a Sony camera coupled to a Macintosh 
IIFX and the image analysis software of Biolab. A stan- 
dard curve made with various dilutions of the amplified 
DNA was prepared to estimate the amount of digested 
DNA from the signal intensity. 
2.8. Histochemistry 
Histochemical methods included modified Gomori's 
trichrome [16], succinic dehydrogenase [17], myosin AT- 
Pase [18] and cytochrome oxidase reactions [19]. Quantita- 
tive data were obtained with a computer-aided semi-auto- 
matic analyser ASM 68K from Leica. 
2.9. Human cytochrome b model 
The human cytochrome b model was derived from 
hydropathic profile calculations based on the human se- 
quence [15] and comparison with other cytochrome b
sequences [10]. The model, made by analogy with that 
proposed for the cytochrome b of several species, includes 
8 transmembrane a-helices and one amphipathic ~-helix 
located between transmembrane h lices III and IV and 
lying on the surface of the intermembrane face of the inner 
mitochondrial membrane. It is widely accepted [20-25]. 
The limits taken for the helices are those defined by Degli 
Esposti et al. [10]. 
Following proteinase K digestion, control and patient 
DNA was extracted either from C1 pellets partially de- 
pleted of mitochondria or from whole muscle, using the 
phenol-chloroform technique. Complete sequence analysis 
of the patient's cytochrome b, described elsewhere [8] 
3. Results 
Fig. 1 summarizes the data for the rates of oxidation of 
substrates entering the respiratory chain via complex I, 
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Fig. 1. Oxidation rate of substrates ntering the mitochondrial respiratory 
chain via complex 1, II or IV. Substrate oxidation for the patient (right) 
and control (left) mitochondria were measured after addition of 80 /xM 
ADP, in the presence of 10 mM glutamate + 1 mM malate, 10 mM 
succinate + 0.6 /zM rotenone or 10 mM ascorbate + 50 /~M tetram- 
ethyl phenylene diamine, as described in Section 2. Control data are 
expressed as the mean of the rates measured for 16 control subjects 
_+ SEM. 
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Fig. 2. Immunological titration of various complex III, IV or V subunits 
in mitochondria from the patient and from controls. For each protein 
tested, the 100% level represents he mean signal intensity measured on 
the same blot for mitochondria from two controls. The bars indicate the 
variability between the two controls. Cytochrome b and subunit II of 
complex IV, both encoded by mitochondrial DNA, are indicated in gray 
and the other proteins, of nuclear origin in white. 
complex II or complex IV. The oxidation rates of gluta- 
mate + malate (complex I) or succinate + rotenone (com- 
plex II) were markedly decreased while that for ascorbate 
+ tetraphenylene diamine (complex IV) was essentially 
unchanged, suggesting that the patient was deficient in 
complex III activity. 
A kinetic study of complex III activity showed that the 
K m for ubiquinol or cytochrome c were not significantly 
modified, while the maximal rate of ubiquinol cytochrome 
c reductase was reduced by approx. 80%, when compared 
to control mitochondria nd expressed per mg of mito- 
chondrial protein (Table 1). It was not feasible to make a 
precise estimation of the amount of cytochrome b in the 
mitochondria by dual-wavelength spectrophotometric anal- 
ysis because of the high amount of sample required for this 
technique. 
Table 1 
Kinetic analysis of Complex III in patient and control mitochondria 
Variable substrate Patient Control 
Ubiquinol 
K m (/zM) 10 10+2 
V m (/xmol • min- ]. mg of protein- i ) 0.3 1.5 + 0.3 
Cytochrome c 
Km (/zM) 4 9+3 
V m (/zmol.min- I rag of protein -1) 0.3 1.5+0.3 
Ubiquinol-cytochrome-c r ductase activity was measured at 37°C, as 
described inthe Section 2, in the presence ofeither 50/zM cytochrome c 
and various concentrations of ubiquinol or in the presence of 60 /zM 
ubiquinol and various concentrations of cytochrome c. Cytochrome ¢
reduction was followed by the difference in the spectra t 550 and 540 
nm (extinction coefficient 19.0 mM- ]. cm- i according to [42]). K m and 
V m were determined from three different control mitochondrial prepara- 
tions. For each preparation, the best estimates of the K m and V m were 
calculated by least square analysis. Data are given as the mean of the 
three different estimations + the SEM. 
However, the levels of complex III subunits have been 
compared by immunological assay, to those of subunits II 
and IV of cytochrome oxidase and to that of the subunit /3 
of F1-ATPase in the mitochondria of the patient and of 
controls (Fig. 2). Although this technique is quantitatively 
much less precise than the spectrophotometric determina- 
tion of cytochrome b, it gives an idea of the relative 
amount of each protein present in patient's mitochondria 
compared with those of controls. Amounts of subunits II 
and IV of cytochrome oxidase and F1-ATPase /3 subunit 
in the patient were normal while those of the complex III 
subunits were decreased. This decrease was barely signifi- 
cant for core I + core II subunits, cytochrome c~ or the 
13.4 kDa protein while the levels of cytochrome b, the 
iron-sulfur protein and the 9.5 kDa protein were only about 
20 to 30% of those seen in control mitochondria, which 
could explain the low maximal rate of ubiquinol cy- 
tochrome c reductase activity seen in the patient and might 
be related to the instability of assembled complex III (see 
below). 
This lack of stability of the patient complex III activity 
was demonstrated by 4°C incubation of mitochondria pre- 
sent in an homogenate freshly prepared from muscle stored 
in liquid nitrogen. Fig. 3 shows that while the control 
complex III activity was as stable at 4°C as at 37°C, the 
patient's complex III activity had decreased by 50%, after 
7 h of incubation at 4°C, and, in contrast, remained stable 
at 37°C for at least 10 h. 
The sensitivity of the patient's complex III to inhibitors 
known to bind to different loci on complex III was tested 
(Fig. 4). The inhibitory effect of myxothiazol on ubiquinol 
cytochrome c reductase was very similar on mitochondria 
from the patient and controls, while that of antimycin A 
was drastically reduced in the case of the patient's mito- 
chondria, with the concentration required for 50% of inhi- 
bition of ubiquinol cytochrome c reductase activity being 
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Fig. 3. Influence of temperature on the stability of ubiqninol cytochrome c reductase. Ubiquinol cytochrome c reductase activity was measured on a 
freshly prepared muscle homogenate, asdescribed in Section 2. The muscle homogenate was incubated either in an ice bucket at 0-4°C or in a water bath 
at 37°C. At the indicated times, samples were withdrawn from the muscle homogenate prepared from the patient (empty squares) or from a control (black 
diamonds) to measure the ubiquinol cytochrome c reductase activity. 
about 0.03 and 1.1 nmol antimycin A per mg of protein in 
control and patient mitochondria, respectively, i.e. an in- 
crease of more than 35-fold in the patient. 
In several species, cytochrome b mutations have been 
correlated with a loss of antimycin A sensitivity [25]; these 
data therefore suggested that such a mutation in this 
patient might be responsible for the observed ecrease in 
antimycin A sensitivity. Sequencing of the patient's cy- 
tochrome b showed two differences from the Cambridge 
sequence [15], T to C and a G to A mutations at nu- 
cleotides 14766 and 15615 of the mtDNA sequence, re- 
spectively, replacing Ile 7 with Thr and Gly290 with Asp 
[8]. The first mutation results in the loss of an MseI 
restriction site in the mtDNA; MseI restriction of a cy- 
tochrome b fragment amplified by PCR and spanning 
nucleotides 14640 to 14815 should thus give rise to frag- 
ments of 127, 28, 17 and 4 bp in the control Cambridge 
sequence and to fragments of 144, 28 and 4 bp in the 
absence of the MseI site, as in mutation T14766C. Fig. 5 
shows that a sample from a control, N1, gave one 144 bp 
band and the expected band at 127 bp, the presence of the 
144 bp band being due to incomplete cleavage, while 
samples from both the patient and another control, N2, 
gave a 144 bp fragment and bands smaller than 50 bp 
which were difficult to visualize. The absence of the 127 
bp band, noted with samples from the patient and several 
control subjects uch as N2, results from a polymorphism, 
which is apparently frequent in Caucasians [5] and there- 
fore unlikely to be related to the complex III deficiency. In 
fact, Fig. 4 shows that the specific activity of ubiquinol 
cytochrome c reductase and the sensitivity to antimycin A
were similar in mitochondria prepared from control N1 
(with mtDNA having the MseI site at position 14766) and 
from control N2 (mtDNA lacking this site), confirming 
that this mutation does not affect these properties of 
complex III. 
Fig. 6 shows that the 341 bp fragment, spanning nu- 
cleotides 15437 to 15777, amplified from the DNA ex- 
tracted from the patient's muscle, could be partially cleaved 
by Aat II into two fragments of 182 and 159 bp, while no 
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Fig. 4. Inhibition of ubiquinol cytochrome c reductase by antimycin A (left) or myxothiazol (right) in patient (black squares) or control mitochondria. 
Controls with (triangles) or without (empty squares) the T 1 4 7 6 6 C  mutation in mtDNA were used. Ubiquinol cytochrome c reductase activity was measured 
as described under Table 1, using 100 /,~M cytochrome c and 60/zM decylubiquinol. Myxothiazol and antimycin A were dissolved in ethanol. 100% of 
activity corresponds to 1.3, 1.4 and 0.3 /zmol. rain- i .mg of protein- ] for controls with or without, the above mutation and for the patient, respectively. 
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Fig. 5. Cytochrome b polymorphism at position 14766 revealed by 
restriction with Mse I. The mtDNA of the patient P and of two controls, 
Nl and N2, was amplified by PCR between positions 14640 and 14815 of 
human mtDNA [15]. The fragments were digested by 5 units of Mse I for 
3 h at 65°C under mineral oil, then separated by agarose gel electrophore- 
sis (3% Multipurpose agarose). A: predicted restriction pattern of the 
amplified fragment. The mutation at position 14766 deletes the Mse I 
restriction site. B: agarose gel electrophoresis stained with ethidium 
bromide. Left lane: DNA ladder; - indicates incubation without Mse I 
and + indicates incubation with Mse I. 
such cleavage was seen with control DNA (not shown). 
Increasing the Aat II/DNA ratio resulted in no increase in 
the proportion of cleaved DNA: in lanes 3-5, from digests 
containing increasing amounts of muscle DNA and a fixed 
amount of Aat II, the amount of the 341 bp band and of 
the 182 + 159 bands increased simultaneously and, in all 
cases, about 85% cleavage was obtained. In lanes 1 and 2, 
the 341 bp fragment was amplified from DNA purified 
from the Cl pellet obtained after two successive mitochon- 
drial extractions of the muscle. In this case, the mitochon- 
drial DNA, still bound to the nuclei and cell debris, was 
less extensively cleaved by Aat II (approximately 30%); a 
3-fold increase in the DNA/Aat II ratio had no effect 
(compare lanes 1 and 2). Mse I digestion of the 176 bp 
fragment obtained after amplification of the Cl pellet 
DNA, (as described in Fig. 5) gave the same pattern as that 
seen with muscle DNA (not shown). The incomplete 
cleavage obtained with Aat II therefore suggests hetero- 
plasmy of muscle mtDNA, with the more readily ex- 
tractable mtDNA containing a higher percentage of muta- 
tion. Since the mitochondria located under the sar- 
colemma, at the periphery of the fibre, are easier to extract 
than those inserted between the myofibrils [26], this sug- 
gested that the peripheral mitochondria may contain a 
higher percentage of mutation than mitochondria from 
other origins. 
This result can be correlated with histochemical results 
from the patient. Fig. 7 shows a striking accumulation of 
Aat II site 
0 A 15437 15777 I I I 
Cl Muscle 
11 213 4 51 
0 B 
1000~ bp 
%r- 
300 = - 341 
150- = 182 
159 
Fig. 6. Percentage heteroplasmy of mutation 15615 in muscle or Cl pellet 
from the patient. The mtDNAs from the patient’s whole muscle and the 
Cl pellet prepared as described in Section 2 were amplified by PCR 
between position 15437 and 15777 of human mtDNA [15]. The fragments 
were digested by 3 units of Aat II for 4 h at 37”C, then separated by 
agarose gel electrophoresis (2% Multipurpose agarose). A: predicted 
restriction pattern of the amplified fragment. The mutation at position 
15615 creates an Aat II restriction site. B: agarose gel electrophoresis 
stained with ethidium bromide. Left lane: DNA ladder; 1 and 2: 5 and 10 
~1 of the PCR reaction from the Cl pellet DNA; 3-5: 2, 5 and 10 ~1 of 
the PCR reaction from the whole muscle DNA, after digestion with Aat 
II. 
subsarcolemmal mitochondria, using the modified 
Gomori’s trichrome. In serial cross sections of the vastus 
lateralis muscle, an intense reaction was seen at the periph- 
ery of all type I fibres (negative for myofibrillar ATPase 
activity at pH 9.4, as shown in Fig. 8A), with the succinic 
dehydrogenase (Fig. 8B) and the cytochrome oxidase stains 
(Fig. IX). In dd’t’ a 1 ion, the percentage of type I fibres, 
determined by counting 400 fibres, was of 63% instead of 
Fig. 7. Mitochondrial aggregates in a muscle cross section. A normal 
fibre (left) is surrounded by others harbouring red-stained ragged subsar- 
colemmal mitochondrial aggregates with moditied Gomori’s trichrome 
stain. Scale bar = 50 Km. 
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Fig. 8. Histochemistry on serial muscle cross-sections. The clear type 1 fibres are more abundant than the dark type 2 ones and exhibit increased activity of 
succinic dehydrogenase and cytochrome oxidase within subsarcolemmal mitochondrial ggregates. A: myofibrillar ATPase, B: succinic dehydrogenase, C: 
cytochrome oxidase. Scale bar = 100 /zm. Numbers indicates ome type 2 fibres that can be followed by their shape in the serial sections. 
the normal 36% seen for the same muscle (vastus lateralis) 
in sedentary adult males, giving a type 1/type 2 ratio of 
1.7 for the patient and 0.6 for controls. 
4. Discussion 
A complex III deficiency in the muscle mitochondria of 
the reported patient was first suggested by the low oxygen 
consumption, observed with either glutamate + malate or 
with succinate + rotenone, and the normal respiration with 
ascorbate + tetramethyl phenylene diamine. Taylor et al. 
[27] have shown that complex III has a much greater effect 
on electron flux via succinate cytochrome c reductase in 
muscle than in other tissues such as liver. It is therefore 
not surprising that a decrease in the maximal rate of 
ubiquinol cytochrome c reductase activity induced such a 
dramatic decrease in the rate of substrate oxidation. 
Histochemical analysis of the patient's muscle biopsy 
demonstrated an increase in the relative amount of type I 
fibres, when compared to the same muscle of healthy 
non-athletes control males, and a striking accumulation of 
mitochondria under the sarcolemma of all such fibres, that 
is a common finding in other human respiratory chain 
defects. The increase in the proportion of oxidative type I 
fibers means that, in the deficient muscle, a compensation 
has taken place in which the production of these fibers 
have been induced by an as yet unknown mechanism. The 
fact that it is those mitochondria, which are most readily 
extractable from muscle, which contain a higher proportion 
of mutated DNA suggests that the defective mitochondria 
accumulate under the sarcolemma. Indeed, the percentage 
of DNA containing the G15615A mutation in whole muscle 
(about 85%) is higher than in the C1 pellet (about 30%) 
obtained after two successive mitochondrial extractions of 
muscle. In animal muscle, it has been shown that the 
mitochondria located under the sarcolemma are much eas- 
ier to extract han those inserted between the myofibrils 
[26], suggesting that, in the muscle fiber, intact mitochon- 
dria remain near the myofibrils where they will be most 
effective in muscle contraction. This observation might 
help to explain the threshold effect often reported in 
mitochondrial pathology in which 80 to 90% of the mtDNA 
must be mutated before any serious clinical signs are seen 
[28]. 
The complex III deficiency detected in this patient was 
due to a decrease in the maximal rate of ubiquinol cy- 
tochrome c reductase activity, thus blocking the electron 
flux through the respiratory chain. The Krn of the complex 
for ubiquinol or cytochrome c was not significantly differ- 
ent from that of control mitochondria suggesting that the 
decreased activity might be linked to a defect in biogene- 
sis, assembly or stability of the complex. Immunological 
studies using a polyclonal antiserum directed against vari- 
ous complex III subunits demonstrated that, while several 
other subunits (the /3 subunit of ATP synthase or subunit 
II or IV of cytochrome oxidase) were present in normal 
quantities and the amounts of core protein I and II, cy- 
tochrome cl and the 13.4 kDa proteins were not signifi- 
cantly different from those in control mitochondria, the 
amounts of cytochrome b, the iron-sulfur protein and the 
9.5 kDa protein were all markedly decreased. It cannot be 
ascertained that the immunological titration of cytochrome 
b present in the mitochondria s as precise as would be a 
spectrophotometric titration (which cannot be performed 
with the limited amount of mitochondria obtained in a 
human biopsy). However, the immunological titration indi- 
cates that cytochrome b, the Fe-S protein and the 9.5 kDa 
protein are present in an amount corresponding toabout 20 
to 30% of the controls. Similarly, there is about 20% of 
residual ubiquinol cytochrome c reductase activity. It is 
likely that this activity corresponds to the amount of 
correctly assembled complex and that the turnover of the 
assembled complex, if it could be expressed as activity per 
mole of assembled cytochrome b, would not be affected 
by the mutation. The mutation induces an assembly and 
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stability defect with a simultaneous decrease of cy- 
tochrome b, the Fe-S protein and the 9.5 kDa protein. 
When a complex is assembled and the Fe-S and 9.5 kDa 
subunit inserted, the complex therefore seems as active as 
the native complex, although the structure may be dis- 
torted, if a mutation is present. Similarly, in yeast mutants, 
mutations on the 11 kDa subunit (homologous to the 
human 9.5 kDa subunit) or on the 14 kDa subunit were 
associated to a coordinated ecrease of the 11 kDa subunit, 
of the Fe-S protein and of cytochrome b [29,30]. However, 
in the patient mitochondria, the 14 kDa subunit was not 
lowered, a phenomenon that has not been observed in 
yeast. 
The immunological data show that the cytochrome b 
mutation does not modify the amount of core protein I and 
II, cytochrome cl and the 13.4 kDa protein present in the 
mitochondria but does seem to impair the assembly of the 
cytochrome b, the Fe-S protein and the 9.5 kDa protein 
into a functional complex. These results are consistent with 
the model for the structure and assembly of bovine com- 
plex III proposed by Gonzalez-Halphen et al. [31]. Indeed, 
in this model, the 9.5 kDa protein and the iron-sulfur 
protein interact with cytochrome b on the intermembrane 
side of the mitochondrial membrane. If the structure of 
human cytochrome b predicted by analogy with yeast or 
bovine cytochrome b is correct (Fig. 9), the mutation at 
position 15615 which replaces the highly conserved Gly290 
[10] with Asp introduces a negative charge in the trans- 
membrane helix VI of the cytochrome b model, close to 
the outer surface of the inner mitochondrial membrane. 
Since Asp, in addition to being acidic, is also a more bulky 
residue than Gly, the normal interactions between cy- 
tochrome b, the Fe-S protein and the 9.5 kDa protein 
could be disrupted and might well explain the specific 
decrease in the amounts of iron-sulfur and 9.5 kDa pro- 
teins. This suggestion is also consistent with the model of 
assembly of complex III proposed by Hemrika et al. [30]: 
the assembly of the sub-complexes of the various subunits 
occurs before the binding of the 9.5 kDa protein (11 kDa 
in yeast) and of the Fe-S protein (the last to be added), 
after association of the preassembled sub-complexes to 
cytochrome b. The preassembled sub-complexes are resis- 
tant to protease digestion, which explains why they are 
found in normal amounts in the patient mitochondria. The 
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4°C instability of the complex III from the patient' s sample 
suggests that the binding of the 9.5 kDa and (or) the Fe-S 
protein are important in stabilizing complex III. In addi- 
tion, the stability of complex III seen at 37°C in contrast to 
the decrease at 4°C suggests the involvement of membrane 
lipids. As an hypothesis, it could be suggested that lipids 
might be involved in the association between cytochrome 
b, the 9.5 kDa protein and the Fe-S protein. At 37°C, 
phospholipids have a much higher flexibity than at 4°C, 
where they are in a gel structure. Alternatively, some lipids 
might be essential parts of the complex III structure, as 
shown recently by X-ray cristallography in the case of the 
complex IV structure [32]. Freezing the lipid structure at 
4°C might induce a weaker binding of the 9.5 kDa and of 
the Fe-S protein than at 37°C. 
To our knowledge, this is the first report of a human 
cytochrome b mutation inducing a specific antimycin A 
resistance. Myxothiazol resistance has been previously re- 
ported for the platelet mitochondria of a patient with 
intermittent ataxia and lactic acidosis [33] and it was 
suggested that the illness resulted from a mutation in the 
quinol oxidase domain of mitochondrial cytochrome b; 
however, the cytochrome b mutation was not identified. 
Studies performed using antimycin A-resistant yeast mu- 
tants have generally proposed that antimycin A resistance 
is often associated with cytochrome b mutations located in 
the vicinity of center N while myxothiazol resistance is 
associated to mutations located in the vicinity of center P 
(Fig. 9). Sequencing cytochrome b gene from the patient 
discussed in this report [8] has revealed two differences 
when compared to the sequence described by Anderson et 
al. [15]. The first, a T14766 to C change, is a common 
cytochrome b polymorphism [5] which replaces Ile 7 with 
Thr, near the center N of the cytochrome b model, to 
which a number of yeast mutants resistant to antimycin A
have been mapped (Fig. 9). Our data show that antimycin 
A sensitivity was not impaired in the mitochondria from a 
normal individual bearing this polymorphism and thus, the 
polymorphism itself cannot be responsible for the an- 
timycin A resistance, seen in this patient. In addition, this 
TL4766C mutation was homoplasmic, present in the healthy 
mother and sisters of the patient, while the mutation 
G156~sA was heteroplasmic and only found in the complex 
III-deficient patient's muscle [8]. 
Antimycin A binding has been studied in many yeast 
mutants. In 1983, Chevillotte-Brivet al. [34] described 
several antimycin-resistant mutants carrying a missense 
mutation in three exon loci (box1, box4 and box6), which 
resulted in a total loss of both electron transfer activity and 
the high affinity binding site for antimycin. They sug- 
gested that all three portions of the polypeptide chain 
participate in the creation of the antimycin binding site, 
and that the antimycin-binding component was not cy- 
tochrome b itself but that an alteration in cytochrome b
structure caused an effect on the antimycin-binding site. 
However, at that time, the exact location of the various 
mutations was not known. More recently, of the six novel 
missense mitochondrial cytochrome b yeast mutants char- 
acterized by Lemesle-Meunier t al. [35], two, G340E and 
L282F (corresponding to G339 and L28 l, in man) have been 
shown to result in severely impaired stability and assembly 
of the bcl complex and loss of high affinity antimycin 
binding site. In the 8 transmembrane a helices cy- 
tochrome b folding model, yeast L282 (man Lz8 l) is 
located in the loop connecting helices V and VI and yeast 
G340 (man G339) near the end of helix VII, both L282 
(L28 l) and G340 (G339) , facing the intermembrane space. 
All other cytochrome b mutations involving antimycin A 
resistance are generally located on the matrix side of the 
mitochondrial membrane (Fig. 9). Although, this is simply 
a model and not a structure defined by X-ray crystallogra- 
phy, it is consistent with the results obtained by many 
laboratories using different approaches (see reviews 
[10,23-25,36]). In this model, L282 and G340 are located in 
the same area of the cytochrome b structure as G290. It is 
shown that the G340E and L282 F mutations in yeast not 
only induce antimycin A resistance but also impair assem- 
bly of the bcl complex [35]. We here show that, in a 
patient beating a G290D mutation in cytochrome b, the 
stability of complex III is decreased at4°C and the amount 
of cytochrome b, the iron-sulfur protein and the 9.5 kDa 
protein are decreased. This suggests that the G290D cy- 
tochrome b mutation impairs the normal assembly or 
stability of the complex, resulting in a decrease in enzyme 
activity and also in a defective antimycin A binding by a 
mechanism similar to that proposed by Lemesle-Meunier 
et al. [34] for the yeast G340 E and L282F mutants. In 
addition, the observation of van Keulen and Berden [37] 
showing that the 9.5 kDa subunit (yeast 1 1 kDa subunit) 
might be directly involved in the binding of antimycin A is 
also consistent with our conclusions. 
Antimycin A has also been previously reported to cause 
a conformational change in the cytochrome bcl  complex 
resulting in weaker binding of the Rieske iron-sulfur pro- 
tein [38-40]. It is therefore possible that the G290D muta- 
tion which loosened the interaction between cytochrome b,
the iron-sulfur protein and the 9.5 kDa protein prevents 
antimycin A induced inhibition in this way. 
According to the folding model of yeast cytochrome b 
described by Link et al. [23], on top of cytochrome b are 
two extramembranar domains, the loop between helix I 
and II and the helical domain between helices III and IV. 
Between these is a cleft large enough to accommodate 
both the loop between helices V and VI and parts of the 
iron-sulfur protein. Helix VI containing G290 appears to be 
close to yeast N256 (man N255), in the loop linking helices 
V and VI. In this model, the top of helix VI would be 
close to this cleft. Changing a Gly to an Asp could 
therefore easily hinder the normal interaction between 
helix VI and the iron-sulfur protein. Geier et al. [41] have 
shown that, in the yeast mutant N256Y, the association 
between the iron-sulfur protein and cytochrome b was 
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decreased to such an extent hat no iron-sulfur was found 
in the isolated bcl complex; in contrast, its level was 
normal in the original membrane, suggesting that the muta- 
tion N256Y of yeast cytochrome b weakened its interaction 
with the iron-sulfur protein which rendered the complex 
unstable during isolation. In the same study, data obtained 
with various mutants suggested that yeast residues V292 
(equivalent to V29 ~ in human) and yeast M295 (1294) in 
helix VI might contribute to the generation of an hy- 
drophobic left in the binding pocket of ubiquinone, with 
F129 (F128) and I125 (MI24) in helix III; the latter is thought 
to be in close proximity to helix VI. If this model also 
holds for human cytochrome b, the replacement of human 
G290 (G291 in yeast) by a D which is a bulkier and charged 
group, might perturb the structure of this pocket. However, 
in the G290 D human mutation, no change in the apparent 
ubiquinone affinity was seen. In addition, these yeast 
mutants were myxothiazol-resistant rather than antimycin- 
resistant. The most likely explanation is therefore that the 
antimycin A resistance observed in the G290 D human 
mutant is not due to a direct interference between an- 
timycin A and G290 but to an indirect decrease in the 
stability of binding between cytochrome b and the iron- 
sulfur protein. 
In conclusion, although a defect in the interaction be- 
tween cytochrome b and the iron-sulfur protein or the 9.5 
kDa protein is an attractive hypothesis for explaining the 
changes seen in the properties of complex III in this 
patient, it will remain a hypothesis until the determination 
of the crystallographic structure of complex III can show if 
such interaction between the cytochrome b G290 and the 
iron-sulfur protein and/or the 9.5 kDa protein is possible. 
In addition, it would be interesting to create, in a species in 
which it is possible to carry out site directed mutagenesis, 
a cytochrome b mutant homologous to the G290 D human 
mutant o study its effects on the modifications of complex 
III properties and assembly. 
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